BioWorld

June 25, 2004

Amgen Submits Fast-Track Palifermin BLA In Mucositis

Amgen Inc. is requesting U.S. regulatory approval under fast-track guidelines for palifermin, a first-in-class investigational compound for oral mucositis. (BioWorld Today) Read More

FDA To Cardiome: More Data Needed To Clear Oxypurinol

Biogen Idec Forms Parkinson's Deal With Vernalis For $100M

Rejuvenon's $37M Financing To Support Cachexia Product

Anidulafungin Fallout: Vicuron Cutting Expenses, Head Count

Generex Receiving $30M Via Sejong Oralin Licensing Deal

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...